Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors — Stella

stellabeta Find trials matched to me Trial Match

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors — Stella

Recruiting

Back to Pancreatic Ductal Adenocarcinoma trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

Trial locations(5 sites)

Canada

Novartis Investigative Site, Montreal, Quebec

France

Novartis Investigative Site, Vandœuvre-lès-Nancy

Israel

Novartis Investigative Site, Haifa

Novartis Investigative Site, Tel Aviv

Singapore

Novartis Investigative Site, Singapore

Key details

Phase

First-in-human testing

Sponsor

Novartis Pharmaceuticals

Enrollment target

~180 participants

Started

November 2025

Primary completion

May 2029

Age range

18 Years – 100 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov